Date: 2014-07-28
Type of information: Licensing agreement
Compound: antibodies from animal B-lymphocytes using Valneva’s proprietary VIVA|Screen® technology
Company: Valneva (France - Austria) undisclosed global animal health company
Therapeutic area: Veterinary medicine
Type agreement:
Action mechanism: The VIVA|Screen® technology, which integrates the ISAAC technology developed by Toyama University and acquired by Valneva in 2011, is used for the selection and retrieval of unique B-lymphocytes from any species that secrete specific and rare antibodies of interest. With its VIVA|Screen® technology, Valneva supports the discovery of these antibodies through the screening and isolation of antibodies from B-lymphocytes from a target population. The efficiency of VIVA|Screen®, from which even a few B lymphocytes among more than 250 million can be isolated, avoids the use of human and murine antibodies and enables the sequence optimization for their use in a respective targeted species.
Disease:
Details: * On July 28, 2014, Valneva announced the signing of a research collaboration and license agreement with a leading global animal health care company to discover antibodies from animal B-lymphocytes using Valneva’s proprietary VIVA|Screen® technology. The VIVA|Screen® technology, which integrates the ISAAC technology developed by Toyama University and acquired by Valneva in 2011, is used for the selection and retrieval of unique B-lymphocytes from any species that secrete specific and rare antibodies of interest.
Financial terms: Financial details are not disclosed but do include upfront and milestone payments along with future royalties on net sales.
Latest news:
